Seven RCTs were included in the review (387 patients, range 20 to 137). Four trials scored the maximum 5 points on the quality scale; one trial scored 4.
The effect of chromium on glycated haemoglobin in patients with diabetes was not statistically significant compared with placebo (-0.33, 95% CI -0.72 to 0.06; seven RCTs). There was statistically significant heterogeneity, but no significant publication bias for this outcome.
Fasting blood sugar showed a statistically significant reduction with chromium compared with placebo(-0.95, 95% CI -1.42 to -0.49; six RCTs). There was no evidence of statistically significant heterogeneity and no evidence of publication bias for this outcome.
Chromium did not have a statistically significant effect on the secondary outcomes (full results reported in the paper).